Baseline patient characteristics
At baseline, the median patient age was 64 (range, 45–88) years. All patients were Asian with 10 females (76.9%) and 3 males (23.1%). Seven patients (53.8%) had an ECOG-PS of 0, and the remaining patients had a score of 1. Patients had received a median of 3 (range, 1–11) prior anticancer regimens. All patients had received EGFR TKI treatment immediately before study enrollment, including 8 (61.5%) osimertinib; 3 (23.1%) erlotinib, and 2 (15.4%) afatinib. Further details, including baseline characteristics in each cohort, are presented in 